Is Buying Royalty Pharma Stock a Safer Way to Bet on Revolution Medicines?
Revolution Medicines (NASDAQ: RVMD) just got some very good news: The FDA gave the company's RASONQUE breakthrough therapy designation. That could help speed the metastatic pancreatic cancer drug to market. But the stock is up 330% over the past year, so investors are already pricing in a lot of good news. Investors can still get exposure to Revolution Medicines if they buy Royalty Pharma (NASDAQ: RPRX) , while also spreading their risk across a more diversified basket of pharmaceutical products offered by various drug makers. Here's why you may want to do just that. Revolution Medicines describes itself as "a global, commercial-stage oncology company dedicated to discovering, developing and delivering innovative medicines for patients with RAS-addicted cancers." That's a lot if you aren't a healthcare specialist, but the big takeaway is that the company makes drugs to treat cancer. Oncology is a very big field, so Revolution Medicines has many opportunities to develop new therapies. Image source: Getty Images. Continue reading